Crit­ics push back on Alzheimer’s As­so­ci­a­tion ad blitz to get Medicare to change its Aduhelm rul­ing: 'Dead wrong'

The lat­est Alzheimer’s As­so­ci­a­tion ad­ver­tis­ing cam­paign en­cour­ages peo­ple to fight.

Not against the dis­ease or for more re­search or treat­ments, but against the Cen­ters for Medicare and Med­ic­aid Ser­vices. More specif­i­cal­ly, CMS’ re­cent re­im­burse­ment de­ci­sion to on­ly pay for Bio­gen and Ei­sai’s con­tro­ver­sial Alzheimer’s drug Aduhelm for pa­tients in clin­i­cal tri­als.

With CMS’ pre­lim­i­nary de­ci­sion now in a 30-day com­ment pe­ri­od, pa­tient ad­vo­cates’ goal is to con­vince CMS to re­verse its de­ci­sion with a mar­ket­ing blitz and pub­lic pres­sure.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters